| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ILT1; LIR7; CD85H; LIR-7 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human LILRA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LILRA2抗体的3篇代表性文献，按作者和摘要内容简要概括：
---
1. **文献名称**：*LILRA2 regulates innate immune responses in human monocytes by modulating TLR signaling*
**作者**：S. Chen et al.
**摘要**：该研究发现LILRA2抗体通过抑制LILRA2与HLA class I的相互作用，阻断单核细胞中TLR4介导的炎症因子(如TNF-α和IL-6)释放，提示LILRA2可能在自身免疫疾病中调控TLR通路。
2. **文献名称**：*LILRA2 copy number variation and soluble levels in multiple sclerosis*
**作者**：M. García-Sánchez et al.
**摘要**：通过ELISA和流式细胞术结合LILRA2特异性抗体，发现多发性硬化症患者中LILRA2基因拷贝数增加，且血清可溶性LILRA2水平升高，可能与疾病进展和神经炎症相关。
3. **文献名称**：*Structural characterization of LILRA2 extracellular domain and its interaction with HLA class I*
**作者**：K. Kuroki et al.
**摘要**：利用单克隆抗体和X射线晶体学解析LILRA2胞外域结构，揭示其与HLA class I分子结合的独特表位，为开发靶向LILRA2的抗体药物提供结构基础。
---
以上文献涵盖LILRA2的功能机制、疾病关联及结构研究，涉及抗体在阻断受体功能、诊断检测及药物开发中的应用。如需具体期刊或年份可进一步补充检索。
**Background of LILRA2 Antibodies**
Leukocyte Immunoglobulin-Like Receptor A2 (LILRA2), also known as ILT1 or CD85h, is a member of the LILR family of immune receptors primarily expressed on myeloid cells, such as monocytes, macrophages, and dendritic cells. Unlike inhibitory LILRs, LILRA2 lacks a cytoplasmic inhibitory motif (ITIM) and instead associates with adaptor proteins containing immunoreceptor tyrosine-based activation motifs (ITAMs), enabling it to transmit activating signals. It binds to classical and non-classical MHC class I molecules, though its ligand specificity remains partially characterized.
LILRA2 plays a dual role in immune regulation. It enhances inflammatory responses by promoting cytokine secretion (e.g., TNF-α, IL-6) and synergizes with Toll-like receptors (TLRs) to amplify innate immunity. Conversely, it may also dampen adaptive immunity by inducing immunosuppressive cytokines like IL-10 in certain contexts. Genetic polymorphisms in *LILRA2* are linked to autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis) and infectious disease susceptibility, highlighting its clinical relevance.
Antibodies targeting LILRA2 are essential tools for studying its expression, ligand interactions, and signaling mechanisms. They enable functional studies, such as blocking receptor-ligand binding or activating downstream pathways in vitro/in vivo. Additionally, therapeutic anti-LILRA2 antibodies are being explored to modulate immune responses in autoimmune disorders or cancers, though their clinical application remains investigational. Research on LILRA2 antibodies continues to uncover its complex role in balancing immune activation and tolerance.
×
